Kisunla (donanemab) has already been granted market approval in the United States, but in late March, the Europe's medicines regulator (EMA) issued a different assessment.
Kisunla has been developed to slow the progression of Alzheimer's disease in adult patients with amyloid-beta plaques in the brain and mild cognitive impairment or mild dementia...
Eli Lilly requests re-examination of Alzheimer's drug recommendation
Eli Lilly has requested that the EMA re-examine its opinion on the company's Alzheimer's drug, Kisunla, the agency announced on Friday.
Vill du få åtkomst till allt?
Prova 30 dagar för 0 kr.
Inga bindningstider eller kortuppgifter krävs.
Prova nu
Köp en prenumeration
Utforska våra prenumerationslösningar och välj den som passar dina behov.
Välj din prenumeration